Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Evaluation of 89 Compounds for Identification of Substrates for Cynomolgus Monkey CYP2C76, a New Bupropion/Nifedipine Oxidase

Shinya Hosaka, Norie Murayama, Masahiro Satsukawa, Makiko Shimizu, Shotaro Uehara, Hideki Fujino, Kazuhide Iwasaki, Shunsuke Iwano, Yasuhiro Uno and Hiroshi Yamazaki
Drug Metabolism and Disposition January 2015, 43 (1) 27-33; DOI: https://doi.org/10.1124/dmd.114.061275
Shinya Hosaka
Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Tokyo, Japan (S.H., N.M., M.Shi., S.U., S.I., H.Y.); Pharmacokinetics and Safety Research Department, Kaken Pharmaceutical Co., Ltd., Shizuoka, Japan (S.H., M.Sa.); School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan (H.F.); Novartis Pharma K.K., Tokyo, Japan (S.I.); and Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd., Kainan, Japan (K.I., Y.U.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Norie Murayama
Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Tokyo, Japan (S.H., N.M., M.Shi., S.U., S.I., H.Y.); Pharmacokinetics and Safety Research Department, Kaken Pharmaceutical Co., Ltd., Shizuoka, Japan (S.H., M.Sa.); School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan (H.F.); Novartis Pharma K.K., Tokyo, Japan (S.I.); and Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd., Kainan, Japan (K.I., Y.U.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masahiro Satsukawa
Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Tokyo, Japan (S.H., N.M., M.Shi., S.U., S.I., H.Y.); Pharmacokinetics and Safety Research Department, Kaken Pharmaceutical Co., Ltd., Shizuoka, Japan (S.H., M.Sa.); School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan (H.F.); Novartis Pharma K.K., Tokyo, Japan (S.I.); and Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd., Kainan, Japan (K.I., Y.U.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Makiko Shimizu
Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Tokyo, Japan (S.H., N.M., M.Shi., S.U., S.I., H.Y.); Pharmacokinetics and Safety Research Department, Kaken Pharmaceutical Co., Ltd., Shizuoka, Japan (S.H., M.Sa.); School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan (H.F.); Novartis Pharma K.K., Tokyo, Japan (S.I.); and Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd., Kainan, Japan (K.I., Y.U.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shotaro Uehara
Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Tokyo, Japan (S.H., N.M., M.Shi., S.U., S.I., H.Y.); Pharmacokinetics and Safety Research Department, Kaken Pharmaceutical Co., Ltd., Shizuoka, Japan (S.H., M.Sa.); School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan (H.F.); Novartis Pharma K.K., Tokyo, Japan (S.I.); and Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd., Kainan, Japan (K.I., Y.U.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hideki Fujino
Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Tokyo, Japan (S.H., N.M., M.Shi., S.U., S.I., H.Y.); Pharmacokinetics and Safety Research Department, Kaken Pharmaceutical Co., Ltd., Shizuoka, Japan (S.H., M.Sa.); School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan (H.F.); Novartis Pharma K.K., Tokyo, Japan (S.I.); and Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd., Kainan, Japan (K.I., Y.U.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazuhide Iwasaki
Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Tokyo, Japan (S.H., N.M., M.Shi., S.U., S.I., H.Y.); Pharmacokinetics and Safety Research Department, Kaken Pharmaceutical Co., Ltd., Shizuoka, Japan (S.H., M.Sa.); School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan (H.F.); Novartis Pharma K.K., Tokyo, Japan (S.I.); and Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd., Kainan, Japan (K.I., Y.U.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shunsuke Iwano
Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Tokyo, Japan (S.H., N.M., M.Shi., S.U., S.I., H.Y.); Pharmacokinetics and Safety Research Department, Kaken Pharmaceutical Co., Ltd., Shizuoka, Japan (S.H., M.Sa.); School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan (H.F.); Novartis Pharma K.K., Tokyo, Japan (S.I.); and Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd., Kainan, Japan (K.I., Y.U.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasuhiro Uno
Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Tokyo, Japan (S.H., N.M., M.Shi., S.U., S.I., H.Y.); Pharmacokinetics and Safety Research Department, Kaken Pharmaceutical Co., Ltd., Shizuoka, Japan (S.H., M.Sa.); School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan (H.F.); Novartis Pharma K.K., Tokyo, Japan (S.I.); and Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd., Kainan, Japan (K.I., Y.U.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroshi Yamazaki
Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Tokyo, Japan (S.H., N.M., M.Shi., S.U., S.I., H.Y.); Pharmacokinetics and Safety Research Department, Kaken Pharmaceutical Co., Ltd., Shizuoka, Japan (S.H., M.Sa.); School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan (H.F.); Novartis Pharma K.K., Tokyo, Japan (S.I.); and Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd., Kainan, Japan (K.I., Y.U.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Cynomolgus monkeys are widely used in preclinical studies during drug development because of their evolutionary closeness to humans, including their cytochrome P450s (P450s). Most cynomolgus monkey P450s are almost identical (≥90%) to human P450s; however, CYP2C76 has low sequence identity (approximately 80%) to any human CYP2Cs. Although CYP2C76 has no ortholog in humans and is partly responsible for species differences in drug metabolism between cynomolgus monkeys and humans, a broad evaluation of potential substrates for CYP2C76 has not yet been conducted. In this study, a screening of 89 marketed compounds, including human CYP2C and non-CYP2C substrates or inhibitors, was conducted to find potential CYP2C76 substrates. Among the compounds screened, 19 chemicals were identified as substrates for CYP2C76, including substrates for human CYP1A2 (7-ethoxyresorufin), CYP2B6 (bupropion), CYP2D6 (dextromethorphan), and CYP3A4/5 (dextromethorphan and nifedipine), and inhibitors for CYP2B6 (sertraline, clopidogrel, and ticlopidine), CYP2C8 (quercetin), CYP2C19 (ticlopidine and nootkatone), and CYP3A4/5 (troleandomycin). CYP2C76 metabolized a wide variety of the compounds with diverse structures. Among them, bupropion and nifedipine showed high selectivity to CYP2C76. As for nifedipine, CYP2C76 formed methylhydroxylated nifedipine, which was not produced by monkey CYP2C9, CYP2C19, or CYP3A4, as identified by mass spectrometry and estimated by a molecular docking simulation. This unique oxidative metabolite formation of nifedipine could be one of the selective marker reactions of CYP2C76 among the major CYP2Cs and CYP3As tested. These results suggest that monkey CYP2C76 contributes to bupropion hydroxylation and formation of different nifedipine oxidative metabolites as a result of its relatively large substrate cavity.

Footnotes

    • Received September 19, 2014.
    • Accepted October 15, 2014.
  • dx.doi.org/10.1124/dmd.114.061275.

  • Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 43 (1)
Drug Metabolism and Disposition
Vol. 43, Issue 1
1 Jan 2015
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Evaluation of 89 Compounds for Identification of Substrates for Cynomolgus Monkey CYP2C76, a New Bupropion/Nifedipine Oxidase
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Novel CYP2C76 Substrates

Shinya Hosaka, Norie Murayama, Masahiro Satsukawa, Makiko Shimizu, Shotaro Uehara, Hideki Fujino, Kazuhide Iwasaki, Shunsuke Iwano, Yasuhiro Uno and Hiroshi Yamazaki
Drug Metabolism and Disposition January 1, 2015, 43 (1) 27-33; DOI: https://doi.org/10.1124/dmd.114.061275

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Novel CYP2C76 Substrates

Shinya Hosaka, Norie Murayama, Masahiro Satsukawa, Makiko Shimizu, Shotaro Uehara, Hideki Fujino, Kazuhide Iwasaki, Shunsuke Iwano, Yasuhiro Uno and Hiroshi Yamazaki
Drug Metabolism and Disposition January 1, 2015, 43 (1) 27-33; DOI: https://doi.org/10.1124/dmd.114.061275
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Candesartan glucuronide serves as a CYP2C8 inhibitor
  • Role of AADAC on eslicarbazepine acetate hydrolysis
  • Gene expression profile of human intestinal epithelial cells
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics